Expression of β1 Adrenergic Receptor in Vascular Anomalies in Children

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2021 Sep 30

PMID 34590496

Citations 1

Authors

Maria-Corina Stanciulescu

Marius-Calin Popoiu

Anca Maria Cimpean

Vlad-Laurentiu David

Rodica Heredea

Simona Cerbu

Eugen-Sorin Boia

Affiliations

Soon will be listed here.

Abstract

Objective: Controversial, heterogeneous, and inconsistent responses to beta-blockers have been reported in some cases of infantile proliferative hemangiomas. On the basis of these clinical observations, we aimed to examine the β1 adrenergic receptor (β1-AR) protein expression distribution among different types of pediatric vascular anomalies.

Methods: Immunohistochemistry (IHC) was performed for β1-AR on 43 surgical specimens.

Results: We found positive β1-AR IHC staining in all intramuscular hemangiomas, capillary-lymphatic, lymphatic, venous, and combined malformations, and Masson's tumor cases, as well as in 7 of 10 cases of proliferative infantile hemangiomas.

Conclusions: Our research demonstrates, for the first time, the degree of heterogeneous expression of β1-AR among pediatric vascular malformations. Our results support the need for β1-AR assessment in pediatric vascular anomalies to select cases with a robust response to β1-selective blockers. β1-AR assessment may have a strong impact on therapeutic refinement for pediatric vascular anomalies by selecting cases with a stronger response to beta-blockers.

Citing Articles

Genetic inactivation of the β1 adrenergic receptor prevents cerebral cavernous malformations in zebrafish.

Li W, McCurdy S, Lopez-Ramirez M, Lee H, Ginsberg M Elife. 2025; 13.

PMID: 39991834 PMC: 11849999. DOI: 10.7554/eLife.99455.

Genetic Inactivation of the β1 adrenergic receptor prevents Cerebral Cavernous Malformations in zebrafish.

Li W, McCurdy S, Lopez-Ramirez M, Lee H, Ginsberg M bioRxiv. 2024; .

PMID: 38746306 PMC: 11092766. DOI: 10.1101/2024.05.05.592554.

References

Tasani M, Glover M, Martinez A, Shaw L . Atenolol treatment for infantile haemangioma. Br J Dermatol. 2017; 176(5):1400-1402. DOI: 10.1111/bjd.15317. View

Zhang L, Wu H, Yuan W, Zheng J . Propranolol therapy for infantile hemangioma: our experience. Drug Des Devel Ther. 2017; 11:1401-1408. PMC: 5428756. DOI: 10.2147/DDDT.S134808. View

Soliman Y, Khachemoune A . Infantile hemangiomas: our current understanding and treatment options. Dermatol Online J. 2019; 24(9). View

Goss J, Konczyk D, Alomari M, Maclellan R, Greene A . Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma. J Craniofac Surg. 2017; 28(8):2001-2003. DOI: 10.1097/SCS.0000000000004166. View

Navarro-Trivino F, Ruiz-Villaverde R, Naranjo-Sintes R . Infantile hemangioma and β-blockers: When, how, and why?. Actas Dermosifiliogr. 2016; 107(7):601-2. DOI: 10.1016/j.ad.2016.03.007. View

Chakkittakandiyil A, Phillips R, Frieden I, Siegfried E, Lara-Corrales I, Lam J . Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol. 2011; 29(1):28-31. DOI: 10.1111/j.1525-1470.2011.01664.x. View

Yu Z, Cai R, Chang L, Qiu Y, Chen X, Chen Q . Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: A long-term follow-up study. J Dermatol. 2019; 46(5):376-382. DOI: 10.1111/1346-8138.14853. View

Bernabeu-Wittel J, Pereyra-Rodriguez J, Mantrana-Bermejo M, Fernandez-Pineda I, De Agustin J, Conejo-Mir J . [Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. Actas Dermosifiliogr. 2011; 102(7):510-6. DOI: 10.1016/j.ad.2011.02.009. View

Rosbe K, Suh K, Meyer A, Maguiness S, Frieden I . Propranolol in the management of airway infantile hemangiomas. Arch Otolaryngol Head Neck Surg. 2010; 136(7):658-65. DOI: 10.1001/archoto.2010.92. View

10.

Marqueling A, Oza V, Frieden I, Puttgen K . Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013; 30(2):182-91. DOI: 10.1111/pde.12089. View

11.

Chiu Y, Drolet B, Blei F, Carcao M, Fangusaro J, Kelly M . Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 2012; 59(5):934-8. PMC: 3528889. DOI: 10.1002/pbc.24103. View

12.

Hermans D, van Beynum I, Kool L, van de Kerkhof P, Wijnen M, van der Vleuten C . Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol. 2011; 64(5):833-8. DOI: 10.1016/j.jaad.2011.01.025. View

13.

Ozeki M, Kanda K, Kawamoto N, Ohnishi H, Fujino A, Hirayama M . Propranolol as an alternative treatment option for pediatric lymphatic malformation. Tohoku J Exp Med. 2012; 229(1):61-6. DOI: 10.1620/tjem.229.61. View

14.

Calderon-Castrat X, Velasquez F, Castro R, Ballona R . Oral Atenolol for Infantile Hemangioma: Case Series of 46 Infants. Actas Dermosifiliogr (Engl Ed). 2019; 111(1):59-62. DOI: 10.1016/j.ad.2019.03.015. View

15.

Vieira C, Gomes A, Dos Santos L, Almeida D, Hildebrand L, Flores I . Intravascular papillary endothelial hyperplasia in the oral mucosa and jawbones: A collaborative study of 20 cases and a systematic review. J Oral Pathol Med. 2020; 50(1):103-113. DOI: 10.1111/jop.13127. View

16.

Wu J, Hooper E, Laifer-Narin S, Simpson L, Kandel J, Shawber C . Initial Experience With Propranolol Treatment of Lymphatic Anomalies: A Case Series. Pediatrics. 2016; 138(3). PMC: 5005016. DOI: 10.1542/peds.2015-4545. View

17.

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

18.

Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J, Taieb A . Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008; 358(24):2649-51. DOI: 10.1056/NEJMc0708819. View

19.

Leaute-Labreze C, Harper J, Hoeger P . Infantile haemangioma. Lancet. 2017; 390(10089):85-94. DOI: 10.1016/S0140-6736(16)00645-0. View

20.

Vlastarakos P, Papacharalampous G, Chrysostomou M, Tavoulari E, Delidis A, Protopapas D . Propranolol is an effective treatment for airway haemangiomas: a critical analysis and meta-analysis of published interventional studies. Acta Otorhinolaryngol Ital. 2012; 32(4):213-21. PMC: 3468939. View